| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| review article | Q7318358 |
| P50 | author | Su Ern Yeoh | Q96099372 |
| P2093 | author name string | Lindsay Robertson | |
| Ahmad Ramli | |||
| P2860 | cites work | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism | Q24197581 |
| Grading quality of evidence and strength of recommendations | Q24562409 | ||
| Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633053 | ||
| The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism | Q24670353 | ||
| Meta-analysis in clinical trials | Q27860779 | ||
| Oral rivaroxaban for symptomatic venous thromboembolism | Q29620160 | ||
| Long-term consequences of deep vein thrombosis. | Q33539569 | ||
| Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study | Q33895888 | ||
| Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials | Q33910755 | ||
| Risk assessment for recurrent venous thrombosis | Q34153343 | ||
| Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism | Q34179254 | ||
| Aspirin for preventing the recurrence of venous thromboembolism | Q34276812 | ||
| Low-dose aspirin for preventing recurrent venous thromboembolism | Q34309660 | ||
| Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration | Q34435111 | ||
| Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism | Q34655742 | ||
| Dabigatran versus warfarin in the treatment of acute venous thromboembolism | Q35016336 | ||
| Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy | Q35101273 | ||
| Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. | Q35508996 | ||
| Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial | Q36276886 | ||
| Management of venous thromboembolism: a systematic review for a practice guideline | Q36721827 | ||
| Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy | Q36841584 | ||
| Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism | Q37741638 | ||
| Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations | Q38215919 | ||
| Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial | Q38408533 | ||
| Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism | Q40286342 | ||
| Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses | Q40706195 | ||
| Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism | Q42637916 | ||
| Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program | Q42674113 | ||
| The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment. | Q43279758 | ||
| Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators | Q43681404 | ||
| Extended oral anticoagulant therapy after a first episode of pulmonary embolism. | Q44496670 | ||
| Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism | Q44548746 | ||
| Low-intensity versus conventional-intensity warfarin for prevention of recurrent venous thromboembolism | Q44674205 | ||
| Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor | Q44852505 | ||
| The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism | Q45298422 | ||
| Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial | Q46301488 | ||
| Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial | Q46368145 | ||
| Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism | Q46650532 | ||
| Extended use of dabigatran, warfarin, or placebo in venous thromboembolism | Q46848170 | ||
| Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trial | Q47834396 | ||
| Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). | Q47923995 | ||
| Extended prophylaxis of venous thromboembolism with idraparinux | Q49167840 | ||
| Oral rivaroxaban for the treatment of symptomatic pulmonary embolism | Q49168967 | ||
| A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 | ||
| Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale. | Q50660298 | ||
| Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. | Q50974554 | ||
| Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. | Q51574600 | ||
| The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. | Q52811121 | ||
| Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. | Q53850167 | ||
| Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism | Q57317313 | ||
| The Long-Term Clinical Course of Acute Deep Venous Thrombosis | Q64386235 | ||
| Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society | Q67886042 | ||
| Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study | Q73836575 | ||
| 6 versus 30 months anticoagulation for recurrent venous thrombosis in patients with high factor VIII | Q79642715 | ||
| Incidence and mortality of venous thrombosis: a population-based study | Q79969827 | ||
| Deep vein thrombosis | Q81584045 | ||
| Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients | Q81670366 | ||
| Apixaban for extended treatment of venous thromboembolism | Q85631280 | ||
| Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial | Q86415704 | ||
| Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study) | Q87187086 | ||
| Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial | Q95614373 | ||
| P921 | main subject | venous thromboembolism | Q9397786 |
| anticoagulation | Q63279445 | ||
| P304 | page(s) | CD011088 | |
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism | |
| P478 | volume | 12 |
| Q64881632 | Comparison of the Effects of Indobufen and Warfarin in a Rat Model of Adenine-Induced Chronic Kidney Disease. |
| Q92205684 | Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study |
| Q58695607 | Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases |
| Q92849036 | Major cardiovascular and bleeding events with long-term use of aspirin in patients with prior cardiovascular diseases: 1-year follow-up results from the Management of Aspirin-induced Gastrointestinal Complications (MAGIC) study |
| Q92305561 | Prevalence and Overlap of Potential Embolic Sources in Patients With Embolic Stroke of Undetermined Source |
Search more.